secwatch.observer — SEC 8-K summary ====================================== Issuer: International Stem Cell CORP (ISCO) CIK: 0001355790 Form: 8-K Filed at: 2026-09-08T20:03:10+00:00 Accession: 0001683168-26-007007 Event type: m_and_a Sentiment: neutral Materiality: 0.65 Item codes: 2.01, 9.01 LLM model: deepseek-v4-flash:cloud@v2 ISCO completes $25.25M sale of LCT to ATCC; pro forma shows higher continuing losses -------------------------------------------------------------------------------- - Closed sale of Lifeline Cell Technology to ATCC on Sept 1, 2026; base price $25M + $250K add-back, adjusted to $25.688M. - Net cash received at closing $21.688M; $2.6M escrow (working capital + indemnity) held as current asset. - Estimated pre-tax gain on sale $22.174M; after-tax gain $19.316M; income tax payable $258K. - Pro forma continuing net loss: $1.616M (H1 2026), $3.195M (FY2025), $3.199M (FY2024) vs smaller historical losses. - Transaction costs $1.027M; intercompany payable of $9.445M from ISCO to LCT forgiven pre-close. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1355790/000168316826007007/0001683168-26-007007-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1355790/000168316826007007/intlstemcell_8k.htm HTML page: https://secwatch.observer/filing/0001683168-26-007007 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer